Drilldown: Medicines
Medicines > classes 
:
Antidepressant or
Empathogen or
[[:Category:Glaucoma_medications|Glaucoma medication]]
:
Antidepressant or
Empathogen or
[[:Category:Glaucoma_medications|Glaucoma medication]] Use the filters below to narrow your results.
generic:
4-FA (1) ·
5-APB (1) ·
5-MAPB (1) ·
6-APB (1) ·
6-APDB (1) ·
Agomelatine (1) ·
Amoxapine (1) ·
Bimatoprost (1) ·
Brimonidine (1) ·
Butylone (1) ·
Clomipramine (1) ·
Desipramine (1) ·
Dorzolamide (1) ·
Duloxetine (1) ·
Ephylone (1) ·
Ethylone (1) ·
Imipramine (1) ·
Isocarboxazid (1) ·
Latanoprost (1) ·
Levomilnacipran (1) ·
Maprotiline (1) ·
MDA (1) ·
MDAI (1) ·
MDEA (1) ·
MDMA (1) ·
Mephedrone (1) ·
Methylone (1) ·
Milnacipran (1) ·
Moclobemide (1) ·
Nefazodone (1) ·
Phenelzine (1) ·
PMA (1) ·
PMMA (1) ·
Protriptyline (1) ·
Reboxetine (1) ·
Sertraline (1) ·
Tianeptine (1) ·
Tranylcypromine (1) ·
Trimipramine (1)
brand:
None (17) ·
Alphagan P (ophthalmic glaucoma), Mirvaso (topical rosacea) (1) ·
Anafranil (1) ·
Aurorix (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Edronax (1) ·
Fetzima (1) ·
Ludiomil (1) ·
Lumigan (glaucoma), Latisse (eyelash growth) (1) ·
Marplan (1) ·
Nardil (1) ·
Norpramin (1) ·
Parnate (1) ·
Savella (1) ·
Serzone (1) ·
Stablon (1) ·
Surmontil (1) ·
Tofranil (1) ·
Trusopt; with timolol as Cosopt (1) ·
Valdoxan (1) ·
Vivactil (1) ·
Xalatan, Xelpros (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (4) ·
Irreversible non-selective MAO inhibitor (3) ·
MAO inhibitor; monoamine releasing agent (1) ·
MAO inhibitor; serotonin releasing agent (1) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Monoamine releasing agent (3) ·
Monoamine releasing agent; 5-HT2A agonist (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin releasing agent (2) ·
Serotonin releasing agent; 5-HT2A agonist (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1)
uses:
None (34) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
'"`UNIQ--vote-00000415-QINU`"', '"`UNIQ--vote-00000416-QINU`"' (1) ·
'"`UNIQ--vote-00000B08-QINU`"', '"`UNIQ--vote-00000B09-QINU`"' (1) ·
'"`UNIQ--vote-00000D9E-QINU`"', '"`UNIQ--vote-00000D9F-QINU`"', '"`UNIQ--vote-00000DA0-QINU`"' (1) ·
'"`UNIQ--vote-000010CE-QINU`"', '"`UNIQ--vote-000010CF-QINU`"', '"`UNIQ--vote-000010D0-QINU`"' (1)
starting dose:
None (34) ·
1 drop in affected eye(s) TID (monotherapy); BID with timolol (Cosopt) (1) ·
1 drop in the affected eye(s) once daily in the evening (1) ·
1 drop in the affected eye(s) once daily in the evening (Lumigan); Latisse applied to upper lash line at bedtime (1) ·
25 mg (1) ·
Ophthalmic 1 drop in affected eye(s) TID; topical Mirvaso 0.33% gel applied to face daily (1)
preparations:
None (34) ·
0.005% ophthalmic solution (50 mcg/mL); typical 2.5 mL bottle (1) ·
0.01%, 0.03% ophthalmic solution (1) ·
0.1%, 0.15%, 0.2% ophthalmic solutions; 0.33% topical gel; combinations with timolol (Combigan) and brinzolamide (Simbrinza) (1) ·
2% ophthalmic solution (Trusopt); 2%/0.5% fixed combination with timolol (Cosopt, Cosopt PF) (1) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1)
fda max:
routes:
onset:
None (33) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
IOP lowering at 1 hour; max at 2-3 hours (1) ·
IOP lowering at 2 hours; max at 4 hours (1) ·
IOP lowering at 3-4 hours; maximum at 8-12 hours (1) ·
IOP lowering at 4 hours, maximum at 8-12 hours; eyelash effect after 2 months (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1)
duration:
halflife:
None (33) ·
~12 hours (1) ·
~17 minutes (free acid, the active form, in aqueous humor)'"`UNIQ--ref-00000417-QINU`"' (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) ·
~3 hours'"`UNIQ--ref-000010D1-QINU`"' (1) ·
~4 months in erythrocytes (carbonic anhydrase binding in red cells; not relevant to topical IOP duration)'"`UNIQ--ref-00000B0A-QINU`"' (1) ·
~45 minutes (free acid in aqueous humor)'"`UNIQ--ref-00000DA1-QINU`"' (1)
bioavailability:
None (33) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
Topical with measurable systemic absorption (small CA inhibition observed clinically with chronic use)'"`UNIQ--ref-00000B0B-QINU`"' (1) ·
Topical; clinically meaningful systemic absorption can produce systemic α2 effects (somnolence, hypotension), especially in children'"`UNIQ--ref-000010D2-QINU`"' (1) ·
Topical; minimal systemic absorption'"`UNIQ--ref-00000418-QINU`"' (1) ·
Topical; minimal systemic absorption'"`UNIQ--ref-00000DA2-QINU`"' (1) ·
~50% (highly variable) (1)
pregnancy:
None (33) ·
Category C (1) ·
Category C'"`UNIQ--ref-0000008F-QINU`"' (1) ·
Limited data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; weigh against alternatives, though systemic exposure is low.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Limited data; weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (2)
Showing below up to 39 results in range #1 to #39.